BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 09, 2014
 |  BioCentury  |  Emerging Company Profile

Anokion: Developing tolerance

Anokion using antigen-specific tolerance to develop less immunogenic drugs

Anokion S.A. is using its antigen-specific tolerance platform to develop less immunogenic versions of existing drugs. In the longer term, the company wants to use the technology to develop novel autoimmune therapeutics.

For existing protein drugs, Anokion's technology exploits a natural tolerance mechanism by conjugating the parent molecule to multiple copies of a peptide that binds glycophorin A (GYPA). GYPA is a surface protein unique to RBCs.

Circulating RBCs undergo apoptosis at a rate of more than 1% per day and are engulfed by antigen-presenting cells (APCs) in the spleen and liver for presentation to CD4+ and CD8+ T cells. During this process, any engineered protein that is attached to RBCs also will be presented to the immune system and recognized as self.

Products in preclinical testing include tolerogenic forms of asparaginase to treat acute lymphoblastic leukemia (ALL)...

Read the full 680 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >